

## 原著

2017年（平成29年）

\*は他教室への協力

1. Aman M, Ohishi Y, Imamura H, Shinozaki T, Yasutake N, Kato K, Oda Y.

Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.

Hum Pathol. 2017 Jun;64:156-163

2. Bekki H, Kohashi K, Yamada Y, Iura K, Ishii T, Maekawa A, Otsuka H, Yamamoto H, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y.

Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis.

Pathobiology. 2017 Jul;84(3):161-169

3. Bekki H, Yamamoto H, Takizawa K, Iwasaki T, Otsuka H, Yamada Y, Kohashi K, Harimaya K, Iwamoto Y, Oda Y.

Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors.

Pathol Res Pract. 2017 Jun;213(6):674-679

4. Hida R, Yamamoto H, Hirahashi M, Kumagai R, Nishiyama K, Gi T, Esaki M, Kitazono T, Oda Y.

Duodenal Neoplasms of Gastric Phenotype: An Immunohistochemical and Genetic Study With a Practical Approach to the Classification.

Am J Surg Pathol. 2017 Mar;41(3):343-353

5. Hiraki-Hotokebuchi Y, Yamada Y, Kohashi K, Yamamoto H, Endo M, Setsu N, Yuki K, Ito T, Iwamoto Y, Furue M, Oda Y.

Alteration of PDGFR $\beta$ -Akt-mTOR Pathway Signaling in Fibrosarcomatous Transformation of Dermatofibrosarcoma Protuberans.

Hum Pathol. 2017 Sep;67:60-68

6.Imada K, Shiota M, Kuroiwa K, Sugimoto M, Abe T, Kohashi K, Yokomizo A, Eto M, Naito S, Oda Y.

FOXO3a expression regulated by ERK signaling is inversely-correlated with Y-box binding protein 1 expression in prostate cancer.

Prostate. 2017 Feb;77(2):145-153

7.Ishii T, Kohashi K, Ootsuka H, Iura K, Maekawa A, Yamada Y, Bekki H, Yoshimoto M, Yamamoto H, Iwamoto Y, Oda Y.

Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma.

Pathol Res Pract. 2017 Jun;213(6):634-638

8.Iura K, Kohashi K, Ishii T, Maekawa A, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Matsumoto Y, Iwamoto Y, Oda Y.

MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.

Virchows Arch. 2017 Sep; 471(3):383–392

9.Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Harimaya K, Iwamoto Y, Oda Y.

Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.

Hum Pathol. 2017 Mar;61:130-139

10.Kuma Y, Yamada Y, Yamamoto H, Kohashi K, Ito T, Furue M, Oda Y.

A Novel Fusion Gene CRT3-MAML2 in Hidradenoma: Histopathological Significance.

Hum Pathol. 2017 Dec;70:55-61

11.Miyazaki T, Ohishi Y, Miyasaka Y, Oda Y, Aishima S, Ozono K, Abe A, Nagai E, Nakamura M, Oda Y.

Molecular Characteristics of Pancreatic Ductal Adenocarcinomas with High-Grade Pancreatic Intraepithelial Neoplasia (PanIN) Are Different from Those without High-Grade PanIN.

Pathobiology. 2017 May;84(4):192-201

12. Oda Y, Aishima S, Shindo K, Fujino M, Mizuuchi Y, Hattori M, Miyazaki T, Tanaka M, Oda Y.

SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas.

Hum Pathol. 2017 Jul;65:71-78

13. Ozono K, Ohishi Y, Onishi H, Nakamura K, Motoshita J, Kato M, Nakanishi R, Nakamura M, Oda Y.

Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma.

Lab Invest. 2017 Nov;97(11):1332-1342

14. Wada T, Ohishi Y, Kaku T, Aman M, Imamura H, Yasutake N, Sonoda K, Kato K, Oda Y.

Endocervical Adenocarcinoma With Morphologic Features of Both Usual and Gastric Types: Clinicopathologic and Immunohistochemical Analyses and High-risk HPV Detection by In Situ Hybridization.

Am J Surg Pathol. 2017 May;41(5):696-705

15. Wang H, Kohashi K, Yoshizumi T, Okumura Y, Tanaka Y, Shimokawa M, Iwasaki T, Aishima S, Maehara Y, Oda Y.

Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.

Hum Pathol. 2017 Jun;64:69-75

16. Yamada Y, Kinoshita I, Kohashi K, Yamamoto H, Kuma Y, Ito T, Koda K, Kisanuki A, Kurosawa M, Yoshimura M, Furue M, Oda Y.

HIF-1 $\alpha$ , MDM2, CDK4, and p16 expression in ischemic fasciitis, focusing on its ischemic condition.

Virchows Arch. 2017 Jul;471(1):117-122

17. Yamada Y, Kuda M, Kohashi K, Yamamoto H, Takemoto J, Ishii T, Iura K, Maekawa A, Bekki H, Ito T, Otsuka H, Kuroda M, Honda Y, Sumiyoshi S, Inoue T, Kinoshita N, Nishida A, Yamashita K, Ito I, Komune S, Taguchi T, Iwamoto Y, Oda Y.

Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes.

Virchows Arch. 2017 Apr;470(4):373-380

18.\*Abe T, Ohuchida K, Endo S, Ookubo F, Mori Y, Nakata K, Miyasaka Y, Manabe T, Ohtsuka T, Nagai E, Oda Y, Nakamura M.  
Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.  
Surgery. 2017 Apr;161(4):951-958

19.\*Akiyama S, Saeki H, Nakashima Y, Iimori M, Kitao H, Oki E, Oda Y, Nakabeppu Y, Kakeji Y, Maehara Y.  
Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma.  
Cancer Med. 2017 Jan;6(1):258-266

20.\*Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, Fujita N, Ohtsuka T, Yoshizumi T, Aishima S, Oda Y, Honda H.  
Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.  
Eur Radiol. 2017 Jun;27(6):2563-2569

21.\*Date K, Ohtsuka T, Fujimoto T, Tamura K, Kimura H, Matsunaga T, Mochidome N, Miyazaki T, Mori Y, Oda Y, Nakamura M, Tanaka M.  
Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.  
Ann Surg. 2017 May;265(5):969-977

22.\*Egashira A, Morita M, Kumagai R, Taguchi KI, Ueda M, Yamaguchi S, Yamamoto M, Minami K, Ikeda Y, Toh Y.  
Neuroendocrine carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 14 cases.  
PLoS One. 2017 Mar 13;12(3):e0173501

23.\*Endo S, Nakata K, Ohuchida K, Takesue S, Nakayama H, Abe T, Koikawa K, Okumura T, Sada M, Horioka K, Zheng B, Mizuuchi Y, Iwamoto C, Murata M, Moriyama T, Miyasaka Y, Ohtsuka T, Mizumoto K, Oda Y, Hashizume M, Nakamura M.  
Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mice.  
Gastroenterology. 2017 May;152(6):1492-1506

24.\*Fujimoto T, Ohtsuka T, Nakashima Y, Gotoh Y, Date K, Mori Y, Sadakari Y, Takahata S, Oda Y, Nakamura M.

Elevated bile amylase level without pancreaticobiliary maljunction is a risk factor for gallbladder carcinoma.

J Hepatobiliary Pancreat Sci. 2017 Feb;24(2):103-108

25.\*Fujishita T, Okamoto T, Akamine T, Takamori S, Takada K, Katsura M, Toyokawa G, Shoji F, Shimokawa M, Oda Y, Nakabeppu Y, Maehara Y.

Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.

Lung Cancer. 2017 Jul;109:52-57

26.\*Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, Moirita K, Shirabe K, Aishima S, Wang H, Oda Y, Honda H.

Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings.

Eur Radiol. 2017 Feb;27(2):498-506

27.\*Fukushima S, Endo M, Matsumoto Y, Fukushi JI, Matsunobu T, Kawaguchi KI, Setsu N, Iida K, Yokoyama N, Nakagawa M, Yahiro K, Oda Y, Iwamoto Y, Nakashima Y. Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.

PLoS One. 2017 May 30;12(5):e0178064

28.\*Haratake N, Toyokawa G, Tagawa T, Kozuma Y, Matsubara T, Takamori S, Akamine T, Yamada Y, Oda Y, Maehara Y.

Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.

Anticancer Res. 2017 Oct;37(10):5713-5717

29.\*Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.

Lung Cancer. 2017 Feb;104:98-105

30.\*Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Soejima Y, Aishima S, Oda Y, Maehara Y.

The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.

Cancer Med. 2017 Jul;6(7):1614-1626

31.\*Ishigami K, Nishie A, Mochidome N, Asayama Y, Ushijima Y, Kakihara D, Okamoto D, Fujita N, Ohtsuka T, Miyasaka Y, Hida T, Yoshizumi T, Honda H

Mucinous nonneoplastic cyst of the pancreas: CT and MRI appearances.

Abdom Radiol (NY). 2017 Dec;42(12):2827-2834

32.\*Kawamoto M, Onishi H, Ozono K, Yamasaki A, Imaizumi A, Kamakura S, Nakano K, Oda Y, Sumimoto H, Nakamura M.

Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer.

Oncotarget. 2017 May 30;8(22):36211-36224

33.\*Kuromi T, Matsushita M, Iwasaki T, Nonaka D, Kuwamoto S, Nagata K, Kato M, Akizuki G, Kitamura Y, Hayashi K.

Association of expression of the hedgehog signal with Merkel cell polyomavirus infection and prognosis of Merkel cell carcinoma.

Hum Pathol. 2017 Nov;69:8-14

34.\*Maehata Y, Nakamura S, Esaki M, Ikeda F, Moriyama T, Hida R, Washio E, Umeno J, Hirahashi M, Kitazono T, Matsumoto T.

Characteristics of Primary and Metachronous Gastric Cancers Discovered after Helicobacter pylori Eradication: A Multicenter Propensity Score-Matched Study.

Gut Liver. 2017 Sep 15;11(5):628-634

35.\*Matsunaga T, Ohtsuka T, Asano K, Kimura H, Ohuchida K, Kitada H, Ideno N, Mori Y, Tokunaga S, Oda Y, Guha S, Raimondo M, Nakamura M, Tanaka M.

S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma.

Pancreas. 2017 Nov/Dec;46(10):1288-1295

36.\*Matsushita M, Iwasaki T, Nonaka D, Kuwamoto S, Nagata K, Kato M, Kitamura Y, Hayashi K.

Higher Expression of Activation-induced Cytidine Deaminase Is Significantly Associated with Merkel Cell Polyomavirus-negative Merkel Cell Carcinomas.

Yonago Acta Med. 2017 Sep 15;60(3):145-153

37.\*Mori H, Kubo M, Yamaguchi R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M.

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.

Oncotarget. 2017 Feb 28;8(9):15584-15592

38.\*Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M. PD-L1 expression in papillary renal cell carcinoma.

BMC Urol. 2017 Jan 13;17(1):8

39.\*Nakaji Y, Oki E, Nakanishi R, Ando K, Sugiyama M, Nakashima Y, Yamashita N, Saeki H, Oda Y, Maehara Y.

Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.

J Cancer Res Clin Oncol, 2017 Jan;143(1):151-160

40.\*Nakayama H, Ohuchida K, Yoshida M, Miyazaki T, Takesue S, Abe T, Endo S, Koikawa K, Okumura T, Moriyama T, Nakata K, Miyasaka Y, Shirahane K, Manabe T, Ohtsuka T, Toma H, Tominaga Y, Nagai E, Mizumoto K, Oda Y, Nakamura M.

Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients.

Oncol Lett. 2017 Sep;14(3):3141-3147.

41.\*Nishimura S, Oki E, Ando K, Iimori M, Nakaji Y, Nakashima Y, Saeki H, Oda Y, Maehara Y.

High ubiquitin-specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer

Cancer Med. 2017 Jun;6(6):1453-1464

42.\*Ohtsuka T, Mori Y, Ishigami K, Fujimoto T, Miyasaka Y, Nakata K, Ohuchida K, Nagai E, Oda Y, Shimizu S, Nakamura M.

Clinical significance of circumportal pancreas, a rare congenital anomaly, in pancreatectomy.

Am J Surg. 2017 Aug;214(2):267-272

43.\*Oki E, Okano S, Saeki H, Umemoto Y, Teraishi K, Nakaji Y, Ando K, Zaito Y, Yamashita N, Sugiyama M, Nakashima Y, Ohgaki K, Oda Y, Maehara Y.

Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.

Oncology 2017 Dec;93(6):387-394

44.\*Okumura T, Ohuchida K, Sada M, Abe T, Endo S, Koikawa K, Iwamoto C, Miura D, Mizuuchi Y, Moriyama T, Nakata K, Miyasaka Y, Manabe T, Ohtsuka T, Nagai E, Mizumoto K, Oda Y, Hashizume M, Nakamura M.

Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells.

Oncotarget. 2017 Mar 14;8(11):18280-18295

45.\*Sonoda K, Yahata H, Okugawa K, Kaneki E, Nakatsuki K, Naka M, Terado N, Ookubo F, Oda Y, Kaku T, Kato K.

Isthmic-vaginal cytological findings after trachelectomy for early-stage cervical cancer.

Cytopathology. 2017 Jun;28(3):243-245

46.\*Taguchi H, Xie Y, Horikoshi N, Maehara K, Harada A, Nogami J, Sato K, Arimura Y, Osakabe A, Kujirai T, Iwasaki T, Semba Y, Tachibana T, Kimura H, Ohkawa Y,

Kurumizaka H. Crystal Structure and Characterization of Novel Human Histone H3 Variants, H3.6, H3.7, and H3.8.

Biochemistry. 2017 Apr 25;56(16):2184-2196

47.\*Taguchi T, Ieiri S, Miyoshi K, Kohashi K, Oda Y, Kubota A, Watanabe Y, Matsufuji H, Fukuzawa M, Tomomasa T.

The incidence and outcome of allied disorders of Hirschsprung's disease in Japan: Results from a nationwide survey.

Asian J Surg. 2017 Jan;40(1):29-34



48.\*Takamori S, Toyokawa G, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.

Anticancer Res. 2017 Aug;37(8):4223-4228.

49.\*Takada K, Okamoto T, Tominaga M, Teraishi K, Akamine T, Takamori S, Katsura M, Toyokawa G, Shoji F, Okamoto M, Oda Y, Hoshino T, Maehara Y.

Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.

PLoS One. 2017 Jul 20;12(7):e0181598.

50.\*Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.

The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.

Lung Cancer. 2017 Feb;104:7-15

51.\*Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Honda H, Oda Y, Maehara Y.

Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.

Cancer Med. 2017 Nov;6(11):2552-2561

52.\*Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.

A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.

Clin Lung Cancer. 2017 Sep;18(5):572-582.e1

53.\*Takada K, Toyokawa G, Tagawa T, Kohashi K, Akamine T, Takamori S, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y.

Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer.

Anticancer Res. 2017 Dec;37(12):7073-7082

54.\*Tanaka K, Yamashita N, Sagara Y, Ohi Y, Taguchi K, Ohno S, Okano S, Oda Y,  
Maehara Y.

The relationship between the expression of FOXA1 and GATA3 and the efficacy of  
neoadjuvant endocrine therapy.

Breast Cancer. 2017 May;24(3):384-392.

55.\*Toyokawa G, Takada K, Okamoto T, Kawanami S, Kozuma Y, Matsubara T,  
Haratake N, Takamori S, Akamine T, Katsura M, Yamada Y, Shoji F, Baba S, Kamitani T,  
Oda Y, Honda H, Maehara Y.

Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic  
Stage I Lung Adenocarcinoma.

Ann Thorac Surg. 2017 Jun;103(6):1750-1757

56.\*Toyokawa G, Takada K, Okamoto T, Kozuma Y, Matsubara T, Haratake N,  
Takamori S, Akamine T, Katsura M, Shoji F, Oda Y, Maehara Y.

High Frequency of Programmed Death-ligand 1 Expression in Emphysematous  
Bullae-associated Lung Adenocarcinomas.

Clin Lung Cancer. 2017 Sep;18(5):504-511.e1.

57.\*Toyokawa G, Takada K, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T,  
Takamori S, Katsura M, Shoji F, Hamamoto R, Oda Y, Maehara Y.

Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of  
EZH2 in Non-small Cell Lung Cancer.

Anticancer Res. 2017 Mar;37(3):1393-1401

58.\*Toyokawa G, Takada K, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T,  
Haratake N, Takamori S, Akamine T, Katsura M, Shoji F, Oda Y, Maehara Y.

Computed Tomography Features of Lung Adenocarcinomas With Programmed Death  
Ligand 1 Expression.

Clin Lung Cancer. 2017 Nov;18(6):e375-e383

59.\*Tsurumaru D, Miyasaka M, Muraki T, Nishie A, Asayama Y, Oki E, Oda Y, Honda H.

Histopathologic diversity of gastric cancers: Relationship between enhancement pattern on  
dynamic contrast-enhanced CT and histological type.

Eur J Radiol. 2017 Dec;97:90-95

60.\*Tsurumaru D, Miyasaka M, Muraki T, Asayama Y, Nishie A, Oki E, Hirahashi M, Hida T, Honda H.

Diffuse-type gastric cancer: specific enhancement pattern on multiphasic contrast-enhanced computed tomography.

Jpn J Radiol. 2017 Jun;35(6):289-295

61.\*Tsutsumi S, Saeki H, Nakashima Y, Ito S, Oki E, Morita M, Oda Y, Okano S, Maehara Y.

Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.

Cancer Sci. 2017 Jun;108(6):1119-1127

62.\*Ueda K, Kawabe K, Lee L, Tachibana Y, Fujimori N, Igarashi H, Oda Y, Jensen RT, Takayanagi R, Ito T.

Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma.

Pancreas. 2017 Apr;46(4):476-481

63.\*Xiaopeng B, Tanaka Y, Ihara E, Hirano K, Nakano K, Hirano M, Oda Y, Nakamura K. Trypsin induces biphasic muscle contraction and relaxation via transient receptor potential vanilloid 1 and neurokinin receptors 1/2 in porcine esophageal body.

Eur J Pharmacol. 2017 Feb 15;797:65-74

64.\*Yamashita K, Kohashi K, Yamada Y, Nishida Y, Urakawa H, Oda Y, Toyokuni S.

Primary extraskeletal osteosarcoma: a clinicopathological study of 18 cases focusing on MDM2 amplification status.

Hum Pathol. 2017 May;63:63-69

65.\*Yanagi Y, Nakayama K, Taguchi T, Enosawa S, Tamura T, Yoshimaru K, Matsuura T, Hayashida M, Kohashi K, Oda Y, Yamaza T, Kobayashi E.

In vivo and ex vivo methods of growing a liver bud through tissue connection.

Sci Rep. 2017 Oct 26;7(1):14085

66.\*Yoshimaru K, Taguchi T, Obata S, Takemoto J, Takahashi Y, Iwanaka T, Yanagi Y, Kuda M, Miyoshi K, Matsuura T, Kinoshita Y, Yoshioka T, Nakazawa A, Oda Y. Immunostaining for Hu C/D and CD56 is useful for a definitive histopathological diagnosis of congenital and acquired isolated hypoganglionosis.

Virchows Arch. 2017 Jun;470(6):679-685

67.\*Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Nabeshima K. Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours.

Histopathology. 2017 Dec;71(6):1011-1014

68.\*大岩俊夫、大岩久夫、沖英次、藤原美奈子、保利喜史  
若年性大腸癌

臨床と研究 2017 Dec;94(12):1543-1550